Gastroparesis Drug Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| CAGR | 4.50 % |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Low |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Gastroparesis Drug Market Analysis
The Gastroparesis Drug Market is expected to register a CAGR of 4.5% over the forecast period.
In patients with chronic gastrointestinal illnesses, COVID-19 initially created a lot of complications as viruses have historically been implicated in complications of gastrointestinal disorders, including gastroparesis. According to an article published by PubMed Central in March 2022, patients suffering from COVID-19 can present with a variety of GI symptoms, such as diarrhea, anorexia, nausea, and vomiting, and can be associated with several GI conditions such as liver injury, GI bleeding, acute cholecystitis, and acute pancreatitis among others. Moreover, according to an article published by PubMed in December 2022, the COVID-19 pandemic significantly reduced the number of gastrointestinal endoscopy procedures necessary for diagnosing gastroparesis. Thus, the increasing complications of gastroparesis and the reduction in gastrointestinal endoscopy procedures significantly impacted market growth. However, as the pandemic has subsided currently, the studied market is expected to have stable growth during the forecast period of the study.
Several factors, such as the increase in the incidence rate of the diabetic population, the rise in the number of surgical procedures, and the growth in the geriatric population, are among the key driving factors for the gastroparesis drug market. Gastroparesis is a disorder affecting mostly type1 and type2 diabetic patients. In this disorder, the stomach takes too long to empty its contents. Drugs, such as erythromycin, antiemetics, and Reglan, are prescribed for treating gastroparesis. Moreover, according to the data from clinicaaltrials.gov in December 2022, there are 60 ongoing clinical trials for gastroparesis drugs due to the high prevalence of type1 type2 diabetes. This drives the demand for these drugs and will further fuel the overall market to a certain extent.
Moreover, according to an article published by Frontline Medical Communications Inc. in April 2022, it is estimated that classic gastroparesis has a prevalence of about 10 per 100,000 population in men and 30 per 100,000 in women, and women are being affected 3 to 4 times more than men. A Major Risk factor for classic gastroparesis is diabetes mellitus (DM), which affects up to 5% of patients with type 1 DM. Thus, the increasing prevalence of gastroparesis is driving the market's growth.
Furthermore, leading manufacturers continuously fund research and development (R&D) projects to introduce new approaches to existing drug therapy. For instance, in October 2021, Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, announced that the United States FDA had cleared them to proceed with a Phase 2a clinical trial of PCS12852 in patients with moderate to severe gastroparesis, which is an unmet medical need condition for which patients who need an alternative and safer treatment options.
Thus, the factors above, such as the rising prevalence of gastroparesis and continuous funding for research and development (R&D) projects to introduce new approaches to the existing drug therapy of gastroparesis, are expected to enhance the market growth. However, the time-consuming regulatory process and side effects of gastroparesis drugs may hamper the market's growth during the forecast period.
Gastroparesis Drug Market Trends
This section covers the major market trends shaping the Gastroparesis Drug Market according to our research experts:
Diabetic Gastroparesis Segment is Expected to Hold a Significant Share in the Gastroparesis Drug Market Over the Forecast Period
Diabetic gastroparesis (DGp) is considered an autonomic neuropathy condition resulting from long-standing poorly controlled type 1 and type 2 diabetes. The diagnostic workup of DGp first excludes obstruction and other causes, including medications that may mimic delayed/disordered gastric emptying. Some symptoms of diabetic gastroparesis are vomiting, nausea, abdominal bloating, abdominal pain, a feeling of fullness after eating just a few bites, vomiting undigested food eaten a few hours earlier, and acid reflux, among others.
According to an article updated by NCBI in March 2022, upper gastrointestinal symptoms are reported in 11% to 18% of patients with diabetes, out of which most of them are associated with delayed gastric emptying or gastroparesis. Gastroparesis is seen in approximately 4.8% of individuals with type 1 diabetes, 1% of those with type 2 diabetes, and 0.1% of those without diabetes. Although there is a stronger association between type 1 diabetes and gastroparesis, the incidence of gastroparesis is much higher in type 2 diabetes patients, and therefore, gastroparesis associated with type 2 diabetes is seen more frequently. Major factors driving the segment's growth are the increasing prevalence of diabetes, increasing awareness about diabetic gastroparesis, and rising product developments by major market players.
The growing diabetes mellitus population worldwide is a major factor leading to the high demand for diabetic gastroparesis drugs. For instance, According to the data published by IDF in September 2021, it is estimated that approximately 537 million adults will be living with diabetes in 2021, and the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. It is also estimated that 3 in 4 adults with diabetes will live in low- and middle-income countries in 2021. Furthermore, according to an article published by frontiers in March 2022, a study in India showed that the prevalence of diabetes mellitus in India was 9.3%. Among those with diabetes mellitus, 45.8% were aware, 36.1% were on treatment, and 15.7% had it under control. Hence, with the increasing prevalence of diabetes, diabetic gastroparesis is also expected to increase, thus enhancing segment growth.
Furthermore, developments by key market players are also enhancing segment growth. For instance, in December 2021, Evoke's' commercialization partner EVERSANA conducted a GIMOTI Awareness, Trial, and Usage (ATU) study to observe a continued physician and provider awareness, trial, and utilization of GIMOTI (a drug for diabetic gastroparesis) following market developments in the second half of 2021.
Thus, the increasing prevalence of diabetes and developments by key market players are driving the segment's growth.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to hold a major market share in the gastroparesis drug market due to the increasing aging population and the rising number of surgical procedures. The United States dominated the market owing to a large prediabetic population, favorable reimbursement policies, and more awareness about the condition. For instance, according to the data from CDC in June 2022, 96 million people aged 18 years or older have prediabetes (38.0% of the adult United States population). Furthermore, increasing healthcare expenditure, a growing number of hospitals, and the presence of well-established healthcare infrastructure are also responsible for the dominance of the region in the market.
Additionally, according to the data by IDF in September 2021, an estimated 51 million people were living with diabetes in 2021 in North America and the Caribbean region, and this number is projected to rise to 57 million by 2030, and 63 million by 2045. Furthermore, according to the data published by Diabetes Canada in February 2022, it is estimated that the number of people suffering from diabetes including type 1, type 2 diagnosed, and type 2 undiagnosed is 5,719,000 in 2022, and this is expected to rise to 7,277,000 by 2032. Among Canadians, it is estimated that 30% live with diabetes or prediabetes, and only 10% live with diagnosed diabetes. The out-of-pocket cost per year for type 1 diabetes on multiple daily insulin injections is around USD 1,100 to USD 2,600 in 2022.
Furthermore, key developments by major players in the region are expected to boost the market growth. For instance, in July 2022, Evoke Pharma, Inc., a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI (metoclopramide) nasal spray for diabetic gastroparesis, announced that the Canadian Intellectual Property Office granted the company a key patent for its previously submitted application (CA 2984736). The received patent is for GIMOTI's method of use.
Thus, due to factors such as the increasing prevalence of diabetes and developments by major players, are expected to increase the sales of gastroparesis drugs in North America during the forecast period.
Gastroparesis Drug Industry Overview
The market is consolidated in nature due to the presence of very limited players operating globally. Some companies currently dominating the market are Abbott Laboratories (Abbott Arzneimittel GmbH), AbbVie Inc. (Allergan Plc), Cadila Pharmaceuticals, Evoke Pharma, AstraZeneca Plc, Neurogastrx Inc., Bausch Health, Theravance Biopharma, and GlaxoSmithKline Plc.
Gastroparesis Drug Market Leaders
-
Evoke Pharma
-
AstraZeneca
-
Cadila Pharmaceuticals
-
Neurogastrx, Inc.
-
AbbVie Inc. ( Allergan Plc)
*Disclaimer: Major Players sorted in no particular order
Gastroparesis Drug Market News
- In December 2022, Evoke Pharma, Inc. announced that the United States Patent and Trademark Office (USPTO) issued a United States patent No. 11,517,545 under the title 'Treatment of Moderate and Severe Gastroparesis'' which covers the usage of GIMOTI.
- In April 2022, Processa Pharmaceuticals, Inc. enrolled its first patient in the Phase 2A clinical trial of PCS12852 in patients with moderate to severe gastroparesis.
Gastroparesis Drug Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increase in the Incidence Rate of Diabetes
- 4.2.2 Rise in Number of Surgeries
- 4.2.3 Growth in Geriatric Population
-
4.3 Market Restraints
- 4.3.1 Time-consuming Regulatory Process
- 4.3.2 Side Effects of Gastroparesis Drugs
-
4.4 Porter's Five Force Analysis
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value - USD million)
-
5.1 By Drug Class
- 5.1.1 Antiemetic Agents
- 5.1.2 Prokinetic Agents
- 5.1.3 Botulinum Toxin Injections
-
5.2 By Disease Type
- 5.2.1 Diabetic Gastroparesis
- 5.2.2 Post-Surgical Gastroparesis
- 5.2.3 Idiopathic Gastroparesis
- 5.2.4 Other Disease Types
-
5.3 By End User
- 5.3.1 Hospitals
- 5.3.2 Clinics
- 5.3.3 Pharmacies
-
5.4 Geography
- 5.4.1 North America
- 5.4.1.1 United States
- 5.4.1.2 Canada
- 5.4.1.3 Mexico
- 5.4.2 Europe
- 5.4.2.1 Germany
- 5.4.2.2 United Kingdom
- 5.4.2.3 France
- 5.4.2.4 Italy
- 5.4.2.5 Spain
- 5.4.2.6 Rest of Europe
- 5.4.3 Asia-Pacific
- 5.4.3.1 China
- 5.4.3.2 Japan
- 5.4.3.3 India
- 5.4.3.4 Australia
- 5.4.3.5 South Korea
- 5.4.3.6 Rest of Asia-Pacific
- 5.4.4 Middle East and Africa
- 5.4.4.1 GCC
- 5.4.4.2 South Africa
- 5.4.4.3 Rest of Middle East and Africa
- 5.4.5 South America
- 5.4.5.1 Brazil
- 5.4.5.2 Argentina
- 5.4.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 Abbott Laboratories (Abbott Arzneimittel GmbH)
- 6.1.2 AbbVie Inc. (Allergan Plc)
- 6.1.3 Cadila Pharmaceuticals
- 6.1.4 Evoke Pharma
- 6.1.5 AstraZeneca Plc
- 6.1.6 Neurogastrx Inc.
- 6.1.7 Bausch Health
- 6.1.8 Theravance Biopharma
- 6.1.9 GlaxoSmithKline Plc
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityGastroparesis Drug Industry Segmentation
As per the scope of the report, gastroparesis drug is a medication to treat gastroparesis disorder, which in other names means 'stomach paralysis.' It affects the stomach muscles, leading to restriction of proper digestion and causing vomiting and problems related to blood sugar-related problems. The Gastroparesis Drug Market is Segmented by Drug Class (Antiemetic Agents, Prokinetic Agents, and Botulinum Toxin Injections), Disease Type (Diabetic Gastroparesis, Post-Surgical Gastroparesis, Idiopathic Gastroparesis, and Other Disease Types), End User (Hospitals, Clinics, and Pharmacies), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers the value (in USD million) for the above segments.
| By Drug Class | Antiemetic Agents | |
| Prokinetic Agents | ||
| Botulinum Toxin Injections | ||
| By Disease Type | Diabetic Gastroparesis | |
| Post-Surgical Gastroparesis | ||
| Idiopathic Gastroparesis | ||
| Other Disease Types | ||
| By End User | Hospitals | |
| Clinics | ||
| Pharmacies | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Gastroparesis Drug Market Research FAQs
What is the current Global Gastroparesis Drug Market size?
The Global Gastroparesis Drug Market is projected to register a CAGR of 4.5% during the forecast period (2024-2029)
Who are the key players in Global Gastroparesis Drug Market?
Evoke Pharma, AstraZeneca, Cadila Pharmaceuticals, Neurogastrx, Inc. and AbbVie Inc. ( Allergan Plc) are the major companies operating in the Global Gastroparesis Drug Market.
Which is the fastest growing region in Global Gastroparesis Drug Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Global Gastroparesis Drug Market?
In 2024, the North America accounts for the largest market share in Global Gastroparesis Drug Market.
What years does this Global Gastroparesis Drug Market cover?
The report covers the Global Gastroparesis Drug Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Global Gastroparesis Drug Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Global Gastroparesis Drug Industry Report
Statistics for the 2024 Global Gastroparesis Drug market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Global Gastroparesis Drug analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
